D-amphetamine extended release pharmacology
Pro Research Analysisby 
Searched over 200M research papers
d-Amphetamine Extended Release Pharmacology: Pharmacokinetics and Bioavailability
Pharmacokinetics of d-Amphetamine Extended Release Formulations
d-Amphetamine extended-release (ER) formulations are designed to provide a controlled release of the active drug, resulting in sustained plasma concentrations over time. Key pharmacokinetic parameters such as maximum plasma concentration (Cmax), time to maximum concentration (Tmax), area under the curve (AUC), half-life (T1/2), clearance (CL/F), and volume of distribution (Vz/F) have been studied across various age groups and formulations. In children, exposure to amphetamine (Cmax and AUC) decreases with age, likely due to fixed dosing across a range of body weights and increased clearance in older children. The pharmacokinetic profile supports once-daily dosing, with mild adverse events consistent with known amphetamine effects 168.
Bioequivalence and Comparative Bioavailability
Multiple studies have shown that different d-amphetamine ER formulations—including oral suspensions, orally disintegrating tablets (ODT), and tablets—demonstrate comparable bioavailability to standard mixed amphetamine salts ER products (such as Adderall XR) in both adults and children. The geometric mean ratios for Cmax and AUC for d- and l-amphetamine consistently fall within the accepted 80% to 125% range, indicating bioequivalence. This has been observed for both oral suspensions and ODTs, regardless of whether the product is swallowed whole, chewed, or taken as a liquid 2457+2 MORE.
Food and Alcohol Effects on d-Amphetamine ER Pharmacology
Studies evaluating the effect of food on d-amphetamine ER formulations have found no clinically significant impact on the rate or extent of absorption. The pharmacokinetic parameters (Cmax, AUC) remain within the bioequivalence range whether the medication is taken with or without food, although a slight delay in Tmax may occur with food. Similarly, co-administration with alcohol (at concentrations up to 40%) does not significantly alter the pharmacokinetic profile or cause dose dumping, supporting the safety and flexibility of these formulations in real-world settings 2349.
Age-Related Pharmacokinetic Differences
In both children and preschool-aged patients, d-amphetamine ER formulations show consistent pharmacokinetic profiles, with detectable plasma concentrations over 24 hours and parameters supporting once-daily dosing. Clearance and volume of distribution are appropriately weight-normalized, and the safety profile remains consistent across age groups, with only mild to moderate adverse events reported 168.
Conclusion
d-Amphetamine extended-release formulations—including oral suspensions, tablets, and orally disintegrating tablets—demonstrate reliable, sustained pharmacokinetics and are bioequivalent to standard mixed amphetamine salts ER products. These formulations are not significantly affected by food or alcohol, and their pharmacokinetic profiles support once-daily dosing in both adults and children. The safety profile is consistent with known amphetamine effects, making these ER formulations a flexible and effective option for the treatment of ADHD across age groups 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic